This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2014 Apr;15(4):363-4.

doi: 10.1016/S1470-2045(14)70084-1. Epub 2014 Feb 28.

Quality of life as a primary endpoint in ovarian cancer trials

Sven Mahner¹, Alexander Burges²

Affiliations

Affiliations

¹ Department of Gynaecology and Gynaecologic Oncology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany. Electronic address: s.mahner@uke.uni-hamburg.de.
² Ludwig-Maximilians-Universität München Großhadern, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Munich, Germany.

PMID: 24582485
DOI: 10.1016/S1470-2045(14)70084-1

Comment

Quality of life as a primary endpoint in ovarian cancer trials

Sven Mahner et al. Lancet Oncol. 2014 Apr.

. 2014 Apr;15(4):363-4.

doi: 10.1016/S1470-2045(14)70084-1. Epub 2014 Feb 28.

Authors

Sven Mahner¹, Alexander Burges²

Affiliations

¹ Department of Gynaecology and Gynaecologic Oncology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany. Electronic address: s.mahner@uke.uni-hamburg.de.
² Ludwig-Maximilians-Universität München Großhadern, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Munich, Germany.

PMID: 24582485
DOI: 10.1016/S1470-2045(14)70084-1

No abstract available

PubMed Disclaimer

Comment on

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators. Pignata S, et al. Lancet Oncol. 2014 Apr;15(4):396-405. doi: 10.1016/S1470-2045(14)70049-X. Epub 2014 Feb 28. Lancet Oncol. 2014. PMID: 24582486 Clinical Trial.

Similar articles

Mandating prospectively defined endpoints for ovarian cancer phase 2 trials: a strategy to improve the quality of gynecologic cancer clinical research.
Markman M. Markman M. Gynecol Oncol. 2008 Sep;110(3):275-7. doi: 10.1016/j.ygyno.2008.05.014. Epub 2008 Jun 30. Gynecol Oncol. 2008. PMID: 18586312 No abstract available.
Serious ethical dilemma of single-agent pegylated liposomal Doxorubicin employed as a control arm in ovarian cancer chemotherapy trials.
Markman M. Markman M. J Clin Oncol. 2010 Jul 1;28(19):e319-20; author reply e321-2. doi: 10.1200/JCO.2010.28.9934. Epub 2010 Jun 1. J Clin Oncol. 2010. PMID: 20516447 No abstract available.
Primary chemotherapy versus primary surgery for ovarian cancer.
Scaletta G, Plotti F, Aloisi A, Angioli R. Scaletta G, et al. Lancet. 2015 Nov 28;386(10009):2142. doi: 10.1016/S0140-6736(15)01050-8. Lancet. 2015. PMID: 26638962 No abstract available.
[Choice of first-line chemotherapy for advanced ovarian cancer].
Tiuliandin SA. Tiuliandin SA. Vopr Onkol. 1999;45(4):350-4. Vopr Onkol. 1999. PMID: 10532090 Review. Russian. No abstract available.
[Combination chemotherapy with docetaxel and carboplatin for epithelial ovarian cancer].
Misawa H, Ochiai K, Yasuda M, Tanaka T. Misawa H, et al. Nihon Rinsho. 2004 Oct;62 Suppl 10:546-9. Nihon Rinsho. 2004. PMID: 15535305 Review. Japanese. No abstract available.

See all similar articles

Cited by

Presence of gastro-intestinal symptoms in ovarian cancer patients during survivorship: a cross-sectional study from the PROFILES registry.
Rietveld MJA, Husson O, Vos MCC, van de Poll-Franse LV, Ottevanger PBN, Ezendam NPM. Rietveld MJA, et al. Support Care Cancer. 2019 Jun;27(6):2285-2293. doi: 10.1007/s00520-018-4510-9. Epub 2018 Oct 17. Support Care Cancer. 2019. PMID: 30328539 Free PMC article.
Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.
Stark DP, Cook A, Brown JM, Brundage MD, Embleton AC, Kaplan RS, Raja FA, Swart AMW, Velikova G, Qian W, Ledermann JA. Stark DP, et al. Cancer. 2017 Jul 15;123(14):2752-2761. doi: 10.1002/cncr.30657. Epub 2017 Mar 24. Cancer. 2017. PMID: 28339098 Free PMC article. Clinical Trial.
Impacts of Surgery on Symptom Burden and Quality of Life in Pituitary Tumor Patients in the Subacute Post-operative Period.
Waddle MR, Oudenhoven MD, Farin CV, Deal AM, Hoffman R, Yang H, Peterson J, Armstrong TS, Ewend MG, Wu J. Waddle MR, et al. Front Oncol. 2019 Apr 23;9:299. doi: 10.3389/fonc.2019.00299. eCollection 2019. Front Oncol. 2019. PMID: 31065545 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information